FMR LLC ANNOUNCE 5.07% SHAREHOLDING IN ABLYNX

REGULATED INFORMATION

GHENT, Belgium, May 26, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC.

FMR LLC notified that they have increased their shareholding in Ablynx and have exceeded the 5% threshold. FMR LLC now hold 2,753,606 Ablynx shares, which represent 5.07% of the current 54,324,572 outstanding shares of Ablynx.

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx:

Dr Edwin Moses CEO t:   +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e:  [email protected]

Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  [email protected]

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville t:   +44 203 709 5700 e: [email protected]

pdf format of the press release http://hugin.info/137912/R/1923736/689880.pdf

HUG#1923736

You May Also Be Interested In

• Vermon launches Vermon Group, accelerating its growth and expanding its offerings
• Steve Raptis, Prominent Policyholder Coverage Attorney, Joins Crowell & Moring
• New Gundam Anime Series to Debut at San Diego Comic-Con 2026 Panel